UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 8-K
______________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 27, 2012
Skystar Bio-Pharmaceutical Company
(Exact name of registrant as specified in its charter)
______________
| Nevada | 001-34394 | 33-0901534 |
| (State or Other Jurisdiction | (Commission | (I.R.S. Employer |
| of Incorporation) | File Number) | Identification No.) |
4/F Building B Chuangye Square, No. 48 Keji Road,
Gaoxin District, Xi’an, Shaanxi Province, P.R. China
(Address of Principal Executive Office) (Zip Code)
(8629) 8819-3188
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07 Submission of Matters to a Vote of Security Holders
On April 27, 2012, Skystar Bio-Pharmaceutical Company (the “Company”) held its Annual Meeting of Shareholders. Set forth below are the matters voted upon at the meeting and the voting results:
Proposal 1- Election of Directors (with 2,529,755 broker non-votes on this matter):
| | Name | | Votes For | | Votes Withheld |
| | Weibing Lu | | 2,655,555 | | 258,963 |
| | Wei Wen | | 2,655,555 | | 258,963 |
| | Mark D. Chen | | 2,655,555 | | 258,963 |
| | Scott Cramer | | 2,615,555 | | 298,963 |
| | Fan Qiang | | 2,655,555 | | 258,963 |
| | Chengtun Qu | | 2,899,831 | | 14,687 |
| | Weirong Shen | | 2,655,555 | | 258,963 |
Proposal 2- Ratification of the appointment of Crowe Horwath LLP as independent registered public accounting firm of the Company for the fiscal year ending December 31, 2011 (5,379,626 votes for, 59,798 votes against and 4,849 votes abstaining; there were no broker non-votes on this matter).
Pursuant to the foregoing votes, Weibing Lu, Wei Wen, Mark D. Chen, Scott Cramer, Fan Qiang, Chengtun Qu and Weirong Shen were elected to serve as directors, and Crowe Horwath LLP was ratified as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2011.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
None.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| | Skystar Bio-Pharmaceutical Company |
| | | |
| | | |
| | By: | /s/ Bing Mei |
| | | Chief Financial Officer |
| | |
Date: April 27, 2012
